Subtype diversity and emergence of drug resistance in HIV-1 in solapur district of Maharashtra, India
Background and Objectives: Even after four decades, HIV infection remains a global challenge and a leading cause of mortality in adults across the world. Anti-retroviral therapy (ART) that controls HIV viremia, is now available through public health facilities in India but drug resistance, which is likely to develop among these individuals remains poorly studied in India. The objectives of present study are to find out the HIV-1 virus subtypes, drug resistance mutations and HIV-1 drug resistance to NRTI, NNRTI and protease inhibitors in the Solapur district, India.
Materials and Methods: In a cross sectional study, forty two ART-experienced HIV-1-infected patients with CD4+ count < 200 cells ml-1 and viral load (VL) > 3, 000 copies ml-1 were recruited. All patients belonged to Maharashtra State of India near Barshi Solapur and had been on ART treatment for over 5 years. EDTA whole blood from HIV-1-infected patients was centrifuged and the viral nucleic acid was purified from the plasma. Viral nucleic acid was amplified by PCR using protease and reverse transcriptase specific primers. The resulting amplicons were sequenced and studied for mutations. The tools from Stanford University website were used for subtyping of HIV-1 and identification of mutations conferring drug resistance.
Results: In present investigation, HIV-1 subtypes were subtype C in 37 (88.09%), subtype CRF01_AE in 2 (4.76%), and subtype A in 3 patients (7.14%). Drug resistance mutations of NRTI, NNRTI and protease were observed in 15 (37.71%) of 42 patients tested. Drug resistance for NRTI was observed in 12 (28.57%) and for NNRTI in 13 (30.95%) patients. No drug resistance was observed for protease inhibitors.
Conclusion: Considerable HIV-1 drug resistance exists among patients receiving ART from a rural areas of India, suggesting more studies from rural region are required to prevent development of resistance to ART.
2. Beyrer C, Abdool Karim Q. The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS 2013; 8: 306-310.
3. UNIAIDS (2014). 90-90-90 an Ambitious treatment target to help end the AIDS Epidemic. www.unaids.org/en/resources/909090
4. Zuo L, Peng K, Hu Y, Xu Q. Genotypic methods for HIV drug resistance monitoring: the opportunities and challenges faced by China. Curr HIV Res 2019; 17: 225-239.
5. Karade S, Chaturbhuj DN, Sen S, Joshi RK, Kulkarni SS, Shankar S, et al. HIV drug resistance following a decade of the free antiretroviral therapy programme in India: A review. Int J Infect Dis 2018; 66: 33-41.
6. Karade SK, Ghate MV, Chaturbhuj DN, Kadam DB, Shankar S, Gaikwad N, et al. Cross- sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India. Medicine (Baltimore) 2016; 95(37): e4886.
7. Manasa J, Danaviah S, Pillay S, Padayachee P, Mithiyane H, Mkhize C, et al. An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp 2014; (85): 51242. 10.3791/51242.
8. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods 2006; 133: 137-145.
9. Holmes H, Davis C, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001; 92: 141-150.
10. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42: 1608-1618.
11. Kousiappa I, Van De Vijver DAMC, Kostrikis LG. Near full-length genetic analysis of HIV sequences derived from Cyprus: evidence of a highly polyphyletic and evolving infection. AIDS Res Hum Retroviruses 2009;25:727-740.
12. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 2018; 35: 1547-1549.
13. Shafer RW. Rationale and Uses of a Public HIV Drug-Resistance Database. J Infect Dis 2006; 194 Suppl 1(Suppl 1): S51-8.
14. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): e4724.
15. Mathur R, Swaminathan S. National ethical guidelines for biomedical and health research involving human participants 2017: A commentary. Indian J Med Res 2018; 148: 279-283.
16. Rhee S-Y, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, et al. Predictive value of HIV-1 genotypic resistance test interpretation Algorithms. J Infect Dis 2009; 200: 453-463.
17. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. https://apps.who.int/iris/bitstream/handle/10665/186275/9789241509565_eng.pdf
18. Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, et al. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One 2015; 10(2): e0118145.
19. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006; 8: 17-23.
20. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004". AIDS 2006; 20: W13-23.
21. Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, et al. Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy. Curr HIV Res 2012; 10: 532-538.
22. Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, Koppada R, Datkar SR, et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res Hum Retroviruses 2011; 27: 1291-1297.
23. Hingankar NK, Thorat SR, Deshpande A, Rajsekaran S, Chandrasekar C, Kumar S, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis 2012; 54 Suppl 4(Suppl 4): S348-54.
24. Chaturbhuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS, et al. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses 2010; 26: 927-932.
25. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14: 523-531.
26. Balakrishnan P, Saravanan S, Madhavan V, Waldrop G (2011). HIV-1 drug resistance among drug-naïve and HAART treated patients in India: current status. In: Regional health forum, WHO Regional Office for South-East Asia 15(1): PP. 27-43.
27. Unaids Report on the Global Aids Epidemic 2013. https://www.unaids.org/en/resources/documents/2013/20130923_UNAIDS_Global_Report_2013
28. Gartner MJ, Roche M, Churchill MJ, Gorry PR, Flynn JK. Understaning the mechanisms driving the spread of Subtype C HIV-1. EBioMedicine 2020; 53: 102682.
|Issue||Vol 14 No 5 (2022)|
|HIV-1; Antiretroviral therapy; CD4 count; Viral load; Drug resistance|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|